This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example content
Rapid bactericidal in vitro activity against resistant Gram-positive pathogens, including MRSA in cSSTI and penicillin-resistant Streptococcus pneumoniae in CAPˠ1–4
Clinical efficacy has been demonstrated against the following pathogens:†1
| Gram-negative | Gram-positive | |
|---|---|---|
 |
Klebsiella pneumoniae | Staphylococcus aureus (MSSA only) |
| Haemophilius influenzae | Streptococcus pneumoniaeˠ | |
| Haemophilius parainfluenzae | ||
| Escherichia coli |
| Gram-negative | Gram-positive | |
|---|---|---|
 |
Escherichia coli | Staphylococcus aureus (MRSA & MSSA) |
| Klebsiella pneumoniae | Streptococcus pyogenes | |
| Klebsiella oxytoca | Streptococcus agalactiae | |
| Morganella morganii | Streptococcus anginosus group | |
| Streptococcus dysgalactiae |
S.aureus, including methicillin-resistant strains, is a major cause of cSSTI in children and adults5,6
S. pneumoniae is the most common pathogen associated with CAP in childhood.ˠ7-10 S.aureus has also emerged as a key causative pathogen.7-9
Infections caused by these pathogens are associated with increased rates of hospitalisation, complications (e.g. empyema) and mortality5,6,8,11-13
Investigate the outcomes of the Zinforo Phase III clinical trials in adult patients with CAP and cSSTI
†Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
ˠThe available clinical data cannot substantiate efficacy against penicillin non-susceptible strains of S.pneumoniae.1
‡There is no experience with Zinforo in the treatment of CAP in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, severe underlying lung disease, those with PORT Risk Class V, and/or CAP requiring ventilation at presentation, CAP due to methicillin-resistant S. aureus or patients requiring intensive care. Caution is advised when treating such patients.1
Abbreviations
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; MRSA, methicillin-resistant Staphylococcus aureus.
Prescribing Information
Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion
References
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd.
Pfizer accepts no responsibility for the content or services of the linked site.
PP-PFE-GBR-3858. November 2021
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd.
Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to Pfizer medicines or
business which it has provided or reviewed.
PP-PFE-GBR-3859. November 2021